Ask AI
ProCE Banner Series

Experts in the Hot Seat: Navigating HER2 Testing and Targeted Therapy Across Gastric, Colorectal, and Biliary Tract Cancers

This satellite symposium at ASCO GI 2026 will deliver updates on the evolving landscape of HER2-positive gastrointestinal cancers, including gastric/GEJ, colorectal, and biliary tract. Expert faculty will provide insights on optimizing molecular testing, individualizing treatment strategies, and interpreting the latest emerging data presented at the meeting.

  AMA
Who Should Attend

This activity is intended for medical oncologists and other healthcare professionals who treat patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC.

All Events

Experts in the Hot Seat: Navigating HER2 Testing and Targeted Therapy Across Gastric, Colorectal, and Biliary Tract Cancers

Upcoming Events

January

09

2026

6:00 PM - 8:00 PM Pacific Time (PT)

In-person

InterContinental San Francisco, 888 Howard St., San Francisco, California 94103

6:30 PM - 8:00 PM Pacific Time (PT)

Virtual

Topics

GI cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in using evidence-based and guideline-directed best practices in incorporating the latest therapeutic advances in HER2-positive advanced gastric/GEJ cancer, CRC, and BTC. 

Target Audience
This activity is intended for medical oncologists and other healthcare professionals who treat patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Develop evidence-based and expert-recommended therapeutic sequencing strategies for patients with advanced HER2-positive gastric/GEJ cancer, CRC, and BTC
  • Incorporate guideline-recommended HER2 testing and interpretation in clinical practice, encompassing biomarker assessment and the latest clinical evidence for optimal patient care
  • Implement patient-centered and multidisciplinary strategies to proactively manage treatment-related adverse events associated with novel therapies for advanced HER2-positive gastric/GEJ cancer, colorectal cancer (CRC), and biliary tract cancer (BTC)
  • Identify patients most likely to benefit from participation in clinical trials exploring novel HER2-targeted therapies and combinations for gastric/GEJ cancer, colorectal cancer (CRC), and biliary tract cancer (BTC)

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Clinical Care Options, LLC dba Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC dba Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191